Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Primary Sjogren's Syndrome
NCT04496960Phase 2Active, not recruiting
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution in Sjogren's syndrome, sponsored by National Institute of Dental and Craniofacial Research. Started May 2021; status: active, not recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT04496960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04496960.